Free Alerts   Login
Consumer Staples › Fabricated Rubber Products, Nec

VERU Stock Price Correlated With Veru Financials

VERU Stock Price vs. Quarterly
VERU
Income Statement
Cash Flow
Balance Sheet

VERU Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

VERU Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

VERU Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Adage Capital Partners Gp
13,722,222 sh
13,722,222 sh
NEW
$9,880
$9,880
Perceptive Advisors
5,584,699 sh
4,494,821 sh
412%
$4,021
$3,237
Vanguard Group
4,709,876 sh
1,171,033 sh
33%
$3,391
$846
Octagon Capital Advisors
3,800,000 sh
3,800,000 sh
NEW
$2,736
$2,736
AIGH Capital Management
3,438,551 sh
3,438,551 sh
NEW
$2,476
$2,476
Awm Investment Company.
2,750,000 sh
2,750,000 sh
NEW
$1,980
$1,980
Morgan Stanley
2,730,119 sh
-1,079,321 sh
-28%
$1,966
-$773
Maven Securities
2,385,853 sh
2,385,853 sh
NEW
$1,718
$1,718
Janus Henderson Group Plc
2,371,890 sh
2,371,890 sh
NEW
$1,715
$1,715
Altium Capital Management Lp
2,000,000 sh
2,000,000 sh
NEW
$1,440
$1,440
Laurion Capital Management Lp
1,700,000 sh
1,700,000 sh
NEW
$1,224
$1,224
J. Goldman & Co Lp
1,607,500 sh
1,607,500 sh
NEW
$1,157
$1,157
Blackrock.
1,173,445 sh
-2,177 sh
0%
$845
Worth Venture Partners
855,855 sh
855,855 sh
NEW
$616
$616
Alyeska Investment Group,
800,000 sh
800,000 sh
NEW
$576
$576
Ubs Oconnor
700,000 sh
700,000 sh
NEW
$504
$504
Geode Capital Management
662,250 sh
62,143 sh
10%
$477
$45
Potomac Capital Management.
654,000 sh
654,000 sh
NEW
$471
$471
Alpine Global Management
587,001 sh
587,001 sh
NEW
$423
$423
Millennium Management
392,731 sh
-442,853 sh
-53%
$283
-$318
COMPANY PROFILE
Principles of consolidation and nature of operations: Veru Inc. is referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Aspen Park Pharmaceuticals, Inc. (APP) and The Female Health Company Limited, The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”), and The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”). All significant intercompany transactions and accounts have been eliminated in consolidation. The Company is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers. The Company has two operating segments: the Research and Development segment and the Sexual Health Business segment. The Company has multiple drug products under clinical development. Activities related to these potential drug products are included in the Research and Development segment. The Company’s Sexual Health Business segment includes its commercial product, FC2, an FDA-approved product for the dual protection against unintended pregnancy and sexually transmitted infections. During fiscal 2020, the Sexual Health Business segment also included PREBOOST® 4% benzocaine medicated individual wipe for the treatment of premature ejaculation. The PREBOOST® business was sold on December 8, 2020. See Note 2 for additional information. Most of the Company’s net revenues during fiscal 2021 and 2020 were derived from sales of FC2. FC2 has been distributed in either or both commercial (private sector) and public health sector markets in 150 countries. It is marketed to consumers in 22 countries through distributors, public health programs, and/or retailers and in the U.S. by prescription.

Free historical financial statements for Veru Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 49 quarters since 2011. Compare with VERU stock chart to see long term trends.

Data imported from Veru Inc SEC filings. Check original filings before making any investment decision.